Calico Life Sciences Announces that Fosigotifator (ABBV-CLS-7262) for Vanishing White Matter Disease has been Selected for the FDA START Pilot Program
Calico Life Sciences LLC (Calico) announced that its investigational eIF2B activator fosigotifator (ABBV-CLS-7262) has been accepted into the U.S. Food and Drug Administration (FDA) Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program.
To read the full press release: https://www.calicolabs.com/press/calico-life-sciences-announces-that-fosigotifator-abbv-cls-7262-for-vanishing-white-matter-disease-has-been-selected-for-the-fda-start-pilot-program/
To find out more about the FDA’s START Pilot Program: https://www.fda.gov/news-events/press-announcements/fda-launches-pilot-program-help-further-accelerate-development-rare-disease-therapies
